
Meet The Professor: Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer — Part 1 of a 3-Part Series
Breast Cancer Update
00:00
Oral Serds - Can You Do Better Than Full Vestrant?
Oral serds can overcome the issue that full vestrant necessarily cannot because of, you know, lack of oral bioavailability. Not every tumor can just get away with single agent endocrine therapy. We need combinations and such combinations are currently being evaluated in early stage either as an upfront strategy or as a swift strategy.
Play episode from 06:21
Transcript


